Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study (vol 393, pg 889, 2019)

首页> 外文期刊>The Lancet >Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study (vol 393, pg 889, 2019)

【24h】

Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study (vol 393, pg 889, 2019)

机译：治疗性单克隆抗体MAB114靶向埃博拉病毒糖蛋白的安全性，耐受性，药代动力学和免疫原性（VRC 608）：开放标记相1研究（Vol 393，PG 889,2019）

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The Lancet》 |2020年第10238期|共1页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类医药、卫生;
关键词

相似文献

外文文献
中文文献

1. Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study (vol 393, pg 889, 2019) [J] . The Lancet . 2020,第10238期

机译：治疗性单克隆抗体MAB114靶向埃博拉病毒糖蛋白的安全性，耐受性，药代动力学和免疫原性（VRC 608）：开放标记相1研究（Vol 393，PG 889,2019）
2. Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy adults: a randomised, first-in-human phase 1 study [J] . Sivapalasingam Sumathi, Kamal Mohamed, Slim Rabih, Nature reviews Cancer . 2018,第8期

机译：在健康成人中靶向埃博拉病毒糖蛋白的三种人单克隆抗体的共配制鸡尾酒的安全性，药代动力学和免疫原性：随机，第一阶段1研究
3. Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy adults: a randomised, first-in-human phase 1 study [J] . Sivapalasingam Sumathi, Kamal Mohamed, Slim Rabih, The Lancet infectious diseases . 2018,第8期

机译：在健康成人中靶向埃博拉病毒糖蛋白的三种人单克隆抗体的共配制鸡尾酒的安全性，药代动力学和免疫原性：随机，第一阶段1研究
4. Safety tolerability pharmacokinetic characteristics and immunogenicity of MW33: a Phase 1 clinical study of the SARS-CoV-2 RBD-targeting monoclonal antibody [O] . Xianmin Meng, Peipei Wang, Yanqing Xiong, 2021

机译：MW33的安全性耐受性药代动力学特性和免疫原性：SARS-COV-2 RBD靶向单克隆抗体的1阶段1临床研究
5. Assessing the safety and pharmacokinetics of the monoclonal antibodies, VRC07-523LS and PGT121 in HIV negative women in South Africa: study protocol for the CAPRISA 012A randomised controlled phase I trial [O] . Sharana Mahomed, Nigel Garrett, Edmund Capparelli, 2019

机译：评估南非艾滋病毒阴性妇女的单克隆抗体，VRC07-523LS和PGT121的安全性和药代动力学：Caprisa 012A随机控制阶段的研究方案

Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study (vol 393, pg 889, 2019)

著录项

相似文献

相关主题

期刊订阅